Latent Transforming Growth Factor β-Binding Protein 4 Is Downregulated in Esophageal Cancer via Promoter Methylation

Cancer treatment and survivorship statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth factor permissive microenvironment in nasopharyngeal carcinoma

(2012) Han Chen et al.   CANCER LETTERS

Cancer Epigenetics: From Mechanism to Therapy

(2012) Mark A. Dawson et al.   CELL

The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer

(2012) Magdalena Groblewska et al.   FOLIA HISTOCHEMICA ET CYTOBIOLOGICA

The IL1RN Promoter rs4251961 Correlates with IL-1 Receptor Antagonist Concentrations in Human Infection and Is Differentially Regulated by GATA-1

(2011) E. D. Carrol et al.   JOURNAL OF IMMUNOLOGY

Latent TGF-β structure and activation

(2011) Minlong Shi et al.   NATURE

Latent transforming growth factor binding protein 4 (LTBP4) is downregulated in mouse and human DCIS and mammary carcinomas

(2011) Celine Kretschmer et al.   CELLULAR ONCOLOGY

Disruption of calvarial ossification inE2f4mutant embryos correlates with increased proliferation and progenitor cell populations

(2010) Emily S. Miller et al.   CELL CYCLE

The ECM protein LTBP-2 is a suppressor of esophageal squamous cell carcinoma tumor formation but higher tumor expression associates with poor patient outcome

(2010) Stephen Ho Kin Chan et al.   INTERNATIONAL JOURNAL OF CANCER

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Mutations in LTBP4 Cause a Syndrome of Impaired Pulmonary, Gastrointestinal, Genitourinary, Musculoskeletal, and Dermal Development

(2009) Zsolt Urban et al.   AMERICAN JOURNAL OF HUMAN GENETICS

TGF-β Superfamily Signaling in Embryonic Development and Homeostasis

(2009) Mary Y. Wu et al.   DEVELOPMENTAL CELL

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Downregulation of transforming growth factor β (TGFβ) and latent TGFβ binding protein (LTBP)-4 expression in late stage canine mammary tumours

(2009) R. Klopfleisch et al.   VETERINARY JOURNAL

Dual functions for LTBP in lung development: LTBP-4 independently modulates elastogenesis and TGF-β activity

(2008) Branka Dabovic et al.   JOURNAL OF CELLULAR PHYSIOLOGY